25 May 2021 07:00 BST

EMTN programme update: publication of Prospectus 

Following an update by AstraZeneca PLC ("AstraZeneca") of its Euro Medium Term Note ("EMTN") programme established in 2007, the following prospectus has been approved by the Financial Conduct Authority and is available for viewing:

Base Prospectus for the AstraZeneca and AstraZeneca Finance LLC U.S. $10,000,000,000 Euro Medium Term Note Programme (the "Prospectus").

AstraZeneca Finance LLC has been added as an issuer to the EMTN programme for 2021. Securities under the programme may therefore be issued by either AstraZeneca or AstraZeneca Finance LLC, depending on AstraZeneca's requirements. Any securities issued by AstraZeneca Finance LLC will be guaranteed by AstraZeneca.

The last drawdown under the EMTN programme was in 2016.

To view the full document, please paste the following URL into the address bar of your browser.
 

http://www.rns-pdf.londonstockexchange.com/rns/6580Z_1-2021-5-24.pdf

A copy of the above Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at:

https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

AstraZeneca contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Adrian Kemp

Company Secretary

AstraZeneca PLC